Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report.
Aged
Autoantibodies
/ blood
Celiac Disease
/ chemically induced
Diet, Gluten-Free
Glucocorticoids
/ therapeutic use
Humans
Immune Checkpoint Inhibitors
/ adverse effects
Immunoglobulin A
/ blood
Male
Mesothelioma
/ drug therapy
Nivolumab
/ adverse effects
Pleural Neoplasms
/ drug therapy
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Protein Glutamine gamma Glutamyltransferase 2
/ immunology
Proton Pump Inhibitors
/ therapeutic use
Treatment Outcome
case report
celiac disease
digestive toxicity
immune checkpoint inhibitors
immune toxicity
nivolumab
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
10
2021
accepted:
30
11
2021
entrez:
3
1
2022
pubmed:
4
1
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICI) reinvigorate the immune system to recognize and destroy tumor cells. Because of this biological mechanism, patients might develop autoimmune toxicities, notably in the digestive tract (most frequently, hepatitis or colitis). A 70-year-old man with relapsed mesothelioma was treated with nivolumab in 3rd line. He was hospitalized for watery and foul-smelling diarrhea. He underwent gastrointestinal endoscopy, showing duodenitis and villous atrophy and measurement of serum IgA antibodies to tissue transglutaminase (tTG-IgA+), leading to the diagnosis of ICI-induced celiac disease. He was treated with steroids, proton pump inhibitors, and a gluten-free diet. If ICI-induced celiac disease is rare in the literature, increasing reports suggest that celiac disease might represent an underestimated ICI toxicity. This case highlights the necessity of complementary investigation (including tTG-IgA and endoscopic biopsies) in patients with atypical digestive symptoms during immunotherapy.
Identifiants
pubmed: 34975913
doi: 10.3389/fimmu.2021.799666
pmc: PMC8718638
doi:
Substances chimiques
Autoantibodies
0
Glucocorticoids
0
Immune Checkpoint Inhibitors
0
Immunoglobulin A
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Proton Pump Inhibitors
0
TGM2 protein, human
0
Nivolumab
31YO63LBSN
Protein Glutamine gamma Glutamyltransferase 2
EC 2.3.2.13
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
799666Informations de copyright
Copyright © 2021 Leblanc, Hoibian, Boucraut, Ratone, Stoffaes, Dano, Louvel-Perrot, Chanez, Chretien, Madroszyk and Rochigneux.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mod Pathol. 2018 Jun;31(6):965-973
pubmed: 29403081
Am J Med. 2006 Apr;119(4):355.e9-14
pubmed: 16564784
J Immunother Cancer. 2019 Aug 5;7(1):203
pubmed: 31383006
BMC Med. 2019 Jul 23;17(1):142
pubmed: 31331324
Mayo Clin Proc. 2013 Apr;88(4):414-7
pubmed: 23541015
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Gut. 2013 Jan;62(1):43-52
pubmed: 22345659
Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):222-234
pubmed: 29512649
Cureus. 2021 Jun 10;13(6):e15565
pubmed: 34277188
J Thorac Oncol. 2018 Oct;13(10):1569-1576
pubmed: 29908324
Clin Transl Gastroenterol. 2018 Sep 19;9(9):180
pubmed: 30228268
ACG Case Rep J. 2019 Aug 08;6(8):e00158
pubmed: 31737699
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581063
Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):479-87
pubmed: 21780895
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278